High-Grade Glioma – Pipeline Review, H1 2018

Global Markets Direct’s, ‘High-Grade Glioma – Pipeline Review, H1 2018’, provides an overview of the High-Grade Glioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma

The report reviews pipeline therapeutics for High-Grade Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved High-Grade Glioma therapeutics and enlists all their major and minor projects

The report assesses High-Grade Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for High-Grade Glioma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advenchen Laboratories LLC

AngioChem Inc

Arog Pharmaceuticals Inc

Athenex Inc

Bayer AG

Bio-Cancer Treatment International Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

CBT Pharmaceuticals Inc

Celgene Corp

Cellectar Biosciences Inc

Concordia International Corp

DelMar Pharmaceuticals Inc

Eisai Co Ltd

Ipsen SA

Karyopharm Therapeutics Inc

Millennium Pharmaceuticals Inc

Nektar Therapeutics

Northwest Biotherapeutics Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Sanofi

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

TheraBiologics Inc

Tocagen Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

High-Grade Glioma Overview 6

High-Grade Glioma Therapeutics Development 7

High-Grade Glioma Therapeutics Assessment 15

High-Grade Glioma Companies Involved in Therapeutics Development 25

High-Grade Glioma Drug Profiles 38

High-Grade Glioma Dormant Projects 362

High-Grade Glioma Discontinued Products 363

High-Grade Glioma Product Development Milestones 364

Appendix 378

List of Tables

List of Tables

Number of Products under Development for High-Grade Glioma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

High-Grade Glioma Pipeline by AbbVie Inc, H1 2018

High-Grade Glioma Pipeline by Advenchen Laboratories LLC, H1 2018

High-Grade Glioma Pipeline by AngioChem Inc, H1 2018

High-Grade Glioma Pipeline by Arog Pharmaceuticals Inc, H1 2018

High-Grade Glioma Pipeline by Athenex Inc, H1 2018

High-Grade Glioma Pipeline by Bayer AG, H1 2018

High-Grade Glioma Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

High-Grade Glioma Pipeline by Boehringer Ingelheim GmbH, H1 2018

High-Grade Glioma Pipeline by Bristol-Myers Squibb Co, H1 2018

High-Grade Glioma Pipeline by CBT Pharmaceuticals Inc, H1 2018

High-Grade Glioma Pipeline by Celgene Corp, H1 2018

High-Grade Glioma Pipeline by Cellectar Biosciences Inc, H1 2018

High-Grade Glioma Pipeline by Concordia International Corp, H1 2018

High-Grade Glioma Pipeline by DelMar Pharmaceuticals Inc, H1 2018

High-Grade Glioma Pipeline by Eisai Co Ltd, H1 2018

High-Grade Glioma Pipeline by Ipsen SA, H1 2018

High-Grade Glioma Pipeline by Karyopharm Therapeutics Inc, H1 2018

High-Grade Glioma Pipeline by Millennium Pharmaceuticals Inc, H1 2018

High-Grade Glioma Pipeline by Nektar Therapeutics, H1 2018

High-Grade Glioma Pipeline by Northwest Biotherapeutics Inc, H1 2018

High-Grade Glioma Pipeline by Novartis AG, H1 2018

High-Grade Glioma Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

High-Grade Glioma Pipeline by Sanofi, H1 2018

High-Grade Glioma Pipeline by Sorrento Therapeutics Inc, H1 2018

High-Grade Glioma Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

High-Grade Glioma Pipeline by Targepeutics Inc, H1 2018

High-Grade Glioma Pipeline by TheraBiologics Inc, H1 2018

High-Grade Glioma Pipeline by Tocagen Inc, H1 2018

High-Grade Glioma Pipeline by ZIOPHARM Oncology Inc, H1 2018

High-Grade Glioma Dormant Projects, H1 2018

High-Grade Glioma Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for High-Grade Glioma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports